Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733238 · ClinicalTrials.gov registry record · Phase 2
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01733238: Completed Phase 2 study, sponsored by Sierra Oncology LLC - a GSK company.
NCT01733238 is a Phase 2 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01733238, a Phase 2 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.
Primary Outcome
Subjects who had a best response of complete response or partial response as assessed by the investigator
Interventions
- DRUG PNT2258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT01733238 record still lists
NCT01733238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which PNT2258 is the first listed.
NCT01733238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01733238 about?
NCT01733238 is a clinical study titled "Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.
What is the current status of trial NCT01733238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2012-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01733238?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT01733238?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01733238's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia